Mammary Duct Infusion Test in Mastitis Mouse Models: Principles, Methods, and Applications

The mammary duct infusion test in mastitis mouse models is a well-established preclinical technique used to induce experimental mammary inflammation and to evaluate antimicrobial, anti-inflammatory, and immunomodulatory therapies via direct intraductal delivery. By reproducing the pathophysiology of clinical and subclinical mastitis under controlled laboratory conditions, this model supports mechanistic research, drug screening, and dose-optimization studies in line with international animal welfare and biosafety practices. This article provides a comprehensive technical overview of model establishment, sample types, testing items, experimental methods, and typical applications of the mammary duct infusion test in mice.

Technical Overview

The mammary duct infusion test is a refined in vivo experimental procedure in which a defined inoculum—typically a suspension of pathogenic bacteria such as Staphylococcus aureus, Escherichia coli, or Streptococcus uberis, or a purified inflammatory stimulus such as lipopolysaccharide (LPS)—is introduced retrograde through the teat canal into the mammary ductal system of a mouse. This route faithfully mimics the natural ascending-route infection that causes most cases of bovine and human mastitis, making it the gold-standard method for establishing experimental mastitis in rodents.

The model is most commonly established in lactating female mice (for example, C57BL/6 or BALB/c strains) on days 8 to 12 of lactation, when mammary tissue is fully differentiated and most susceptible to intramammary challenge. Following infusion, rapid activation of the innate immune response occurs, characterized by neutrophil infiltration, elevated pro-inflammatory cytokines, disruption of the blood–milk barrier, and histological tissue damage. These endpoints provide quantitative readouts for evaluating candidate therapeutics.

Model Principle

Under anesthesia, the teat orifice of a selected gland (typically the fourth, inguinal pair) is located and gently cannulated with a fine needle (29–33 gauge) or micro-catheter. A small, precisely controlled volume of the challenge material is instilled into the ductal lumen, from which it diffuses through the ductal tree into secretory alveoli. Inflammation develops within hours, reaching a peak response that can be sampled at predefined time points from 6 to 72 hours after challenge.

Animal Welfare and Regulatory Compliance

All procedures must be reviewed and approved by an institutional animal care and use committee (IACUC) or equivalent ethics body, and should follow the 3R principles (replacement, reduction, refinement) and ARRIVE reporting guidelines. Facility and husbandry conditions should conform to applicable national standards such as GB 14925 for laboratory animal environments. Where the test is performed as part of a biological safety evaluation program for medical or veterinary products, animal welfare requirements are aligned with ISO 10993-2. Work with viable pathogens is conducted under appropriate biosafety containment (typically BSL-2) by trained personnel in accredited third-party laboratories or qualified research institutions.

Testing Samples

Test Articles

The mammary duct infusion model accommodates a broad range of test materials intended for the prevention or treatment of mastitis, including:

• Antimicrobial agents and novel antibiotic candidates for intramammary administration
• Non-steroidal and steroidal anti-inflammatory drugs
• Natural product extracts, phytochemicals, and traditional medicine-derived compounds
• Probiotics, bacteriocins, antimicrobial peptides, and bacteriophage preparations
• Monoclonal antibodies, cytokine modulators, and other biologicals
• Vaccine candidates and immunostimulatory adjuvants
• Intramammary sustained-release formulations and drug-delivery systems

Biological Specimens Collected

Upon completion of the observation period, a comprehensive set of biological samples is harvested for analysis, including:

• Mammary gland tissue (ipsilateral challenged gland and contralateral unchallenged control gland)
• Blood, serum, and plasma for hematological and biochemical assays
• Milk or whey fractions from lactating dams
• Mammary tissue homogenates for cytokine, enzyme, and bacterial load assays
• Draining (inguinal) lymph nodes and spleen for systemic immune evaluation
• Fixed tissue blocks for histopathology and immunohistochemistry

Testing Items

A typical study protocol incorporates multiple complementary endpoints that together characterize the inflammatory response and the protective effect of the test article:

• Clinical observation: body weight, rectal temperature, behavior, gland swelling, erythema, and a standardized mastitis clinical score
• Histopathological examination: hematoxylin and eosin (H&E) staining with semi-quantitative tissue injury scoring, alveolar integrity, and inflammatory cell infiltration grading
• Myeloperoxidase (MPO) activity assay as a marker of neutrophil infiltration
• Inflammatory cytokine quantification: TNF-α, IL-1β, IL-6, IL-10, IL-8 (KC), and MCP-1 by ELISA or qRT-PCR
• Signaling pathway analysis: TLR4, MyD88, phosphorylated NF-κB p65, IκBα, and NLRP3 inflammasome components by Western blot or immunohistochemistry
• Oxidative stress markers: superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase (CAT), malondialdehyde (MDA), and reactive oxygen species (ROS)
• Bacterial burden: quantitative colony-forming unit (CFU) enumeration from mammary homogenates to assess microbial clearance
• Hematology: total white blood cell count, neutrophil-to-lymphocyte ratio, and serum acute-phase proteins
• Blood–milk barrier integrity: expression of tight junction proteins occludin, claudin, and ZO-1
• Apoptosis analysis: TUNEL staining and Bax/Bcl-2/caspase-3 expression profiling
• Milk quality indicators in lactating models: somatic cell count, lactose, total protein, and fat content

Testing Methods

Animals and Grouping

Lactating female mice at days 8–12 postpartum are randomized into experimental groups, typically including a normal control group, a mastitis model group, one or more test-article treatment groups at graded doses, and a positive-control drug group. Group sizes are determined by statistical power analysis. Pups may be standardized across litters before the procedure to reduce variability, and investigators performing outcome assessments are blinded to treatment allocation.

Induction of Experimental Mastitis

Mice are anesthetized with inhaled isoflurane or an approved injectable anesthetic. The teat of the target gland is disinfected, and the teat canal is gently entered with a 29–33 gauge needle or fine polyimide cannula attached to a micro-syringe. A challenge suspension—commonly 10² to 10⁶ CFU of the selected pathogen, or 10 to 50 µg of LPS, in 20 to 50 µL of sterile phosphate-buffered saline—is slowly infused into the gland. The contralateral gland typically receives vehicle only and serves as an intra-animal control. Careful technique and slow infusion rates prevent ductal reflux, back-leakage, and pressure-induced artifacts.

Test Article Administration

Depending on the intended clinical use, the test article may be delivered by intramammary co-infusion through the same ductal route, or by systemic administration via intraperitoneal, intravenous, subcutaneous, or oral gavage routes. Dosing is usually initiated at the time of challenge or shortly thereafter, and may be repeated according to the study design. Formulations are prepared under sterile conditions, and physicochemical characteristics such as pH, osmolality, and particulate content are verified before intramammary use.

Observation and Sample Collection

Animals are monitored at scheduled intervals (commonly 6, 12, 24, 48, and 72 hours after induction) for clinical signs and humane endpoints. At the terminal time point, animals are euthanized by an approved method, blood is collected by cardiac puncture, and mammary glands are excised. One portion is fixed in neutral-buffered formalin for histology, while the remainder is snap-frozen or homogenized on ice for cytokine, enzyme activity, oxidative stress, Western blot, and CFU assays.

Analytical Platforms

Quantitative readouts are generated using validated platforms, including sandwich ELISA kits calibrated against international reference standards, real-time quantitative PCR with housekeeping gene normalization, chemiluminescent Western blotting, colorimetric and fluorometric enzyme assays, flow cytometry for immune cell phenotyping, and standard microbiological culture with serial dilution plating for bacterial enumeration.

Biosafety and Quality Control

Studies involving viable pathogens are performed under BSL-2 containment with documented decontamination procedures. Quality assurance measures include cage-side randomization, coded sample processing, duplicate analytical runs, inclusion of positive and negative controls on every assay plate, instrument calibration traceable to recognized metrology standards, and full data-integrity documentation consistent with good laboratory practice expectations. Many sponsors delegate these studies to accredited third-party laboratories to ensure independent, audit-ready data packages.

Applications

The mammary duct infusion test in mice is a versatile platform that supports discovery-phase and translational research across veterinary and biomedical domains:

• Efficacy evaluation of new antibiotics and alternative antimicrobials for the treatment of bovine and small-ruminant mastitis
• Screening of anti-inflammatory natural products and identification of active lead compounds
• Assessment of vaccines, immunomodulators, and passive immunization strategies against mammary pathogens
• Mechanistic investigation of innate immune signaling, including the TLR4/NF-κB and NLRP3 inflammasome pathways
• Studies of blood–milk barrier function and mammary epithelial barrier restoration
• Biomarker discovery and pharmacodynamic profiling for mastitis-related diagnostics
• Preclinical safety and local tolerance assessment of intramammary formulations and delivery devices, complementary to biological evaluation programs conducted under the ISO 10993 series of standards
• Translational modeling of human lactational mastitis and puerperal mammary infection

FAQ

Why is a mouse model used instead of cattle for mastitis infusion studies?

Mice offer substantial advantages in cost, housing, handling, and availability of reagents and genetically defined strains, and they allow adequately powered, multi-group studies with ethical feasibility. The histological and cytokine responses of the mouse mammary gland to intraductal bacterial challenge closely parallel those in bovine mastitis, making the model a well-accepted screening tool before confirmation in target species.

Which mammary gland is typically infused?

The fourth (ingual) pair of abdominal mammary glands is most frequently used because the teats are large, accessible, and the ductal tree is easily cannulated, while the contralateral gland can serve as an internal vehicle control.

What infusion volume is appropriate?

Volumes of 20 to 50 µL are standard. Excessive volumes increase intraductal pressure, cause reflux through the teat canal, and can produce non-specific tissue injury that confounds the inflammatory readout.

How quickly does mastitis develop after infusion?

Pro-inflammatory cytokines rise within 2 to 6 hours, neutrophil infiltration becomes prominent by 12 to 24 hours, and histological damage peaks around 24 to 48 hours, depending on the pathogen and inoculum dose.

How is successful model establishment confirmed?

Confirmation relies on convergent evidence: mammary gland swelling and clinical signs, elevated MPO activity and TNF-α/IL-1β/IL-6 levels, histopathological injury scores significantly above unchallenged controls, and, for infectious models, recoverable CFU from gland homogenates.

Can the same model be used to study drug delivery rather than infection?

Yes. The teat canal cannulation technique is equally applicable to intramammary pharmacokinetic studies, local tolerance testing of infused formulations, and evaluation of sustained-release drug-delivery systems intended for intramammary administration.

What humane endpoints are applied?

Predefined humane endpoints—such as greater than 15–20% body weight loss, severe lethargy, hypothermia, or necrosis at the infusion site—trigger immediate intervention and are specified in the approved animal use protocol, in keeping with 3R principles and national laboratory animal welfare standards.